1. Pharmaxis
2. Home
3. Our Products
4. Compassionate Use Programs

Compassionate Use Programs

Bronchitol^®

Pharmaxis is collaborating with distribution partners around the world to provide Bronchitol® (mannitol) via named patient access programs to people suffering from Cystic Fibrosis or Bronchiectasis.

What is a named patient access program?

A named patient access program is a mechanism that permits the supply of an unlicensed product to a specific healthcare professional for the treatment of an individual patient. Each country has its own regulations that provide a mechanism to allow access to patients who need these medicinal products. The exact requirements for use vary from country to country.

How can I obtain Bronchitol?

Healthcare Professionals in Australia or New Zealand may contact Pharmaxis for information about access to Bronchitol for Compassionate use:

Pharmaxis Medical Information
Phone: +61 2 9454 7226
Email: med.info@pharmaxis.com.au

Healthcare professionals outside of Australia may be able to obtain Bronchitol via a named patient use program by contacting IDIS Limited who specialise in the supply of unlicensed medicines.

IDIS Limited
Tel: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: internationalsales@idispharma.com

Please note that neither Pharmaxis nor IDIS are able to provide advice on the suitability of Bronchitol for, individual patients. Patients wishing to know more about Bronchitol should discuss with their doctor the most suitable treatment for them.